Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

    Annet Bens, Danish Cancer Society Research Center, DenmarkSøren Friis, Danish Cancer Society Research Center, University of Copenhagen, Christian Dehlendorff, Danish Cancer Society Research Center, DenmarkMaj-Britt Jensen, h Danish Breast Cancer Cooperative Group Secretariat, Rigshospitalet , Copenhagen , Denmark., Bent Ejlertsen, University of Copenhagen, DenmarkNiels Kroman, Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.,
  • Deirdre Cronin-Fenton
  • Lene Mellemkjær, Danish Cancer Society Research Center, Denmark

Observational studies of aspirin use and breast cancer risk have provided inconsistent results. The occurrence of contralateral breast cancer (CBC) among breast cancer survivors may serve as a useful high-risk model to identify preventive drug effects. Using this model, we examined the association between post-diagnosis use of low-dose aspirin and risk of CBC. We identified all women recorded with a first primary breast cancer in the Danish Breast Cancer Cooperative Group Database between 1996 and 2012. Information on drug use, tumor and patient characteristics, treatment, and CBC was obtained from nationwide registries. In the main analysis, we defined time-varying post-diagnosis low-dose aspirin use as two or more prescriptions filled during follow-up and applied a one-year exposure lag. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnosis low-dose aspirin use and CBC risk. Among 52,723 breast cancer patients, 1,444 women developed CBC during a median follow-up of 4.8 years. The adjusted HR for CBC associated with post-diagnosis use of low-dose aspirin was 0.91 (95% CI: 0.75-1.09). We observed no substantial variation in HRs according to pattern of low-dose aspirin use or estrogen receptor status of the first or the contralateral breast cancer. In conclusion, this large nationwide cohort study of breast cancer survivors does not provide strong evidence suggesting an association between post-diagnosis use of low-dose aspirin and risk of CBC.

Original languageEnglish
JournalPreventive Medicine
Volume116
Pages (from-to)186-193
Number of pages8
ISSN0091-7435
DOIs
Publication statusPublished - 2018

See relations at Aarhus University Citationformats

ID: 140545922